Akthelia Pharmaceuticals
Akthelia Pharmaceuticals is a pioneering biopharmaceutical company focused on developing therapeutics that enhance the body's innate defense mechanisms to combat debilitating diseases. The company targets mucosal barrier injury and epithelial integrity through a novel immunotherapeutic strategy. Its mission is to revolutionize treatment for diseases such as cancer, infection, and autoimmune disorders by leveraging the body's own microbial defense mechanisms.
Industries
N/A
Nr. of Employees
small (1-50)
Akthelia Pharmaceuticals
Grandagardi 16, 101 Reykjavik, Iceland
Patents
Products
Lead oral small-molecule prophylactic for chemotherapy-induced febrile neutropenia (preclinical)
Preclinical oral small-molecule candidate designed to enhance gastrointestinal epithelial immunity and prevent microbiome translocation and bloodstream infections in immunocompromised chemotherapy patients.
Topical small-molecule candidate for wound healing (preclinical)
Topical formulation candidate intended to enhance skin epithelial immune resilience and accelerate wound regeneration, with a focus on diabetic wounds.
Lead oral small-molecule prophylactic for chemotherapy-induced febrile neutropenia (preclinical)
Preclinical oral small-molecule candidate designed to enhance gastrointestinal epithelial immunity and prevent microbiome translocation and bloodstream infections in immunocompromised chemotherapy patients.
Topical small-molecule candidate for wound healing (preclinical)
Topical formulation candidate intended to enhance skin epithelial immune resilience and accelerate wound regeneration, with a focus on diabetic wounds.
Expertise Areas
- Preclinical drug discovery and lead optimisation
- Mucosal and epithelial immunology therapeutics
- Small-molecule medicinal chemistry
- High-throughput cell-based screening and reporter assay development
Key Technologies
- Small-molecule NCE discovery
- High-throughput cell-based reporter assays
- HDAC inhibition
- STAT3 acetylation modulation
Key People
News & Updates
The article highlights Akthelia's promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) for oncology and inflammatory bowel disorders.
Akthelia received a $350,000 grant from RANNIS to support the development of Gastrimod® (AKT-011) for chemotherapy-induced febrile neutropenia.
Akthelia presented new data on mucosal barrier injury at the Nordic Life Science Days 2024, highlighting their strategic roadmap and partnerships.
Akthelia received the European Commission Seal of Excellence, recognizing its innovative approach in biopharmaceutical development.
The article highlights Akthelia's promising oral NCE therapeutic asset Gastrimod™️ (AKT-011) for oncology and inflammatory bowel disorders.
Akthelia received a $350,000 grant from RANNIS to support the development of Gastrimod® (AKT-011) for chemotherapy-induced febrile neutropenia.
Akthelia presented new data on mucosal barrier injury at the Nordic Life Science Days 2024, highlighting their strategic roadmap and partnerships.
Akthelia received the European Commission Seal of Excellence, recognizing its innovative approach in biopharmaceutical development.